Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00584922 · ClinicalTrials.gov registry record

Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation

A clinical trial of Atrial Fibrillation, sponsored by University of Oklahoma.

Completed
Registry status
175
Enrollment target
1
Study location

NCT00584922 is a study of Atrial Fibrillation that has completed, run by University of Oklahoma. The registered enrollment target is 175 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00584922, a study of Atrial Fibrillation, has completed, sponsored by University of Oklahoma.

COMPLETED
Registry status
175 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to prospectively follow the next 200 patients who undergo catheter ablation of atrial fibrillation for symptoms and signs of esophageal injury.

Conditions Studied

Interventions

  • PROCEDURE Endoscopy in group I (all patients)

Study Locations (1)

Oklahoma

  • OU Medical Center - Oklahoma City

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2006-12-05
Est. Completion 2011-12

Sponsor

University of Oklahoma

358 total trials

What the Registry Record Tells You About NCT00584922

The ClinicalTrials.gov registry entry for NCT00584922 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Endoscopy in group I (all patients) is the first listed.

NCT00584922 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT00584922 about?

NCT00584922 is a clinical study titled "Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation". The purpose of this study is to prospectively follow the next 200 patients who undergo catheter ablation of atrial fibrillation for symptoms and signs of esophageal injury.

What is the current status of trial NCT00584922?

This trial is currently completed. The enrollment target is 175 participants. The study started on 2006-12-05. Estimated completion is 2011-12.

What conditions does trial NCT00584922 study?

This clinical trial studies the following conditions: Atrial Fibrillation.

What interventions are being tested in trial NCT00584922?

The interventions under investigation include: Endoscopy in group I (all patients) (PROCEDURE).

Who is sponsoring clinical trial NCT00584922?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00584922 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.